In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Singapore Gains Momentum As Major R&D, Manufacturing Hub; Sees Double-digit Pharma Sector Growth

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Output of Singapore's biomedical manufacturing cluster increased 14.8 percent last year, according to Singapore's Economic Development Board. Within the cluster, the pharmaceuticals segment grew 15.6 percent with higher levels of production of active pharmaceutical ingredients. Output of the medical technology segment edged up 0.8 percent to meet export orders for surgical and medical instruments

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC074751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel